Lung - Research Protocols
Alliance A151216:
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center
Alliance A081105:
Randomized Double-Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center
ECOG E4512:
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs. Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center
EA5142:
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center
S1400:
(Lung-Map) A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center
CALGB 30610:
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center
For more information about ongoing clinical trials at the Alvin & Lois Lapidus Cancer Institute, please contact the oncology research team at 410-601-6120